The China Phase III PANKU-Lung01 trial reported a substantial blinded-review PFS gain for the EGFR×HER3 bispecific ADC izalontamab brengitecan versus platinum chemotherapy after EGFR TKI progression. The data were presented and published online in…
Source-gap reconciliation: an October 23 primary release and simultaneous Lancet online paper on PANKU-Breast01 were absent from the reviewed Insilens report history. In this China Phase III trial, izalontamab brengitecan prolonged blinded-review PFS versus…
Bristol Myers Squibb reported that the Phase 3 EXCALIBER-RRMM trial met its progression-free survival dual-primary endpoint for iberdomide plus subcutaneous daratumumab and dexamethasone (ZDd). Median progression-free survival was 42 months versus 20 months with…
FDA expanded CAMZYOS to symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients weighing at least 30 kilograms, making mavacamten the first approved therapy specifically for pediatric obstructive HCM. In the randomized Phase 3…
Link Cell Therapies expanded its previously announced $60 million Series A to $90 million. The additional $30 million brings strategic investors including Bristol Myers Squibb and Kyowa Kirin alongside JJDC, Samsara BioCapital, Sheatree Capital…
Bristol Myers Squibb discontinued the Phase I program for ORM-6151, also known as BMS-986497, after reviewing clinical data in AML and MDS. The CD33-targeted degrader-antibody conjugate carried a GSPT1 molecular-glue payload and was the…
Bristol Myers Squibb said the registrational Phase II QUINTESSENTIAL study of arlocabtagene autoleucel met its primary overall-response-rate endpoint and key complete-response-rate endpoint in quadruple-class-exposed relapsed or refractory multiple myeloma after at least four prior…
Peer-reviewed Phase I results for arlocabtagene autoleucel (arlo-cel; BMS-986393; CC-95266), an autologous GPRC5D-directed CAR-T therapy, show clinically meaningful activity in 84 heavily pretreated patients with relapsed or refractory multiple myeloma. Overall response was 87%,…
Bristol Myers Squibb confirmed that it paused autoimmune-disease studies of zolacabtagene autoleucel after life-threatening inflammatory and neurologic adverse events. The pause began in early June but became broadly public on September 4. The company…
Chai Discovery announced a research collaboration under which Bristol Myers Squibb will use Chai’s molecular-folding and generative-design models to support therapeutic-antibody discovery across its portfolio and help build a continuously learning discovery system. The…
